Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.58 |
| ▸ | PDE10A | Q9Y233 | 15/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15537503 | 0.98 | TRPV3 (0.57) | TRPV3PDE10AHRH3 | |
| SCHEMBL6475308 | 0.83 | GAA (0.51) | TRPV3PDE10AHRH3 | |
| SCHEMBL25189276 | 0.83 | HTR3E (0.58) | TRPV3PDE10AHRH3 | |
| SCHEMBL10233469 | 0.82 | PDE10A (0.57) | TRPV3PDE10AHCRTR1HCRTR2 | |
| SCHEMBL20548111 | 0.82 | PDE10A (0.54) | TRPV3PDE10AHCRTR1HCRTR2 | |
| SCHEMBL23207442 | 0.82 | PDE10A (0.54) | TRPV3PDE10AHCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL30152537 | 0.81 | PDE10A (0.52) | TRPV3PDE10AHCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL23167793 | 0.81 | PDE10A (0.52) | TRPV3PDE10AHCRTR1HCRTR2 | |
| SCHEMBL6838679 | 0.80 | HSD11B1 (0.50) | TRPV3PDE10AHSD11B1 | |
| SCHEMBL6242988 | 0.80 | HSD11B1 (0.50) | TRPV3PDE10AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319321-B2 | [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
| US-11168080-B2 | Dynamin-1-like protein inhibitors | MITOBRIDGE, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-11168080-B2 | Dynamin-1-like protein inhibitors | MITOBRIDGE, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200131172-A1 | DYNAMIN-1-LIKE PROTEIN INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2020-04-30 | — | — | US | disclosed |
| US-20200131172-A1 | DYNAMIN-1-LIKE PROTEIN INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2020-04-30 | — | — | US | disclosed |
| US-20200055858-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-20 | — | — | US | disclosed |
| EP-2854804-B1 | PYRROLIDINO HETEROCYCLES | HOFFMANN LA ROCHE (CH) | 2019-11-20 | — | — | EP | disclosed |
| WO-2018200674-A1 | DYNAMIN-1-LIKE PROTEIN INHIBITORS | MITOBRIDGE, INC. (US) | 2018-11-01 | — | — | WO | disclosed |
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2018-08-02 | — | — | US | disclosed |
| US-9540384-B2 | Pyrrolidino heterocycles | HOFFMANN-LA ROCHE, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| EP-2854804-A1 | PYRROLIDINO HETEROCYCLES | F. Hoffmann-La Roche AG (CH) | 2015-04-08 | — | — | EP | disclosed |
| US-20150087644-A1 | PYRROLIDINO HETEROCYCLES | HOFFMANN-LA ROCHE INC. (US) | 2015-03-26 | — | — | US | disclosed |
| WO-2013178569-A1 | PYRROLIDINO HETEROCYCLES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055858-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE12, PDE5A | TRPV3 3616/4885PDE10A 20/4885HRH3 3552/4885 |
| US-11168080-B2 | Dynamin-1-like protein inhibitors | DNM1L, DNM1, DNM2 | TRPV3 3755/4885PDE10A 3209/4885HRH3 4340/4885 |
| US-20150087644-A1 | PYRROLIDINO HETEROCYCLES | PDE3A, PDE3B, PDE2A | TRPV3 1399/4885PDE10A 5/4885HRH3 1713/4885 |
| US-11319321-B2 | [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors | PDE2A, PDE12, PDE5A | TRPV3 3616/4885PDE10A 20/4885HRH3 3552/4885 |
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ADORA2A, ADORA2B, ADORA1 | TRPV3 3793/4885PDE10A 1751/4885HRH3 882/4885 |
| US-20200131172-A1 | DYNAMIN-1-LIKE PROTEIN INHIBITORS | DNM1L, DNM1, DNM2 | TRPV3 3755/4885PDE10A 3209/4885HRH3 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.